(FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -0.82%9.3B | -4.14%6.37B | 0.75%4.12B | 7.38%1.9B | -13.93%9.37B | 0.10%6.65B | -2.96%4.09B | -9.65%1.77B | 35.67%10.89B | 88.35%6.64B |
Operating income | -0.82%9.3B | -4.14%6.37B | 0.75%4.12B | 7.38%1.9B | -13.93%9.37B | 0.10%6.65B | -2.96%4.09B | -9.65%1.77B | 35.67%10.89B | 88.35%6.64B |
Operating expenses | 6.36%-5.95B | 7.43%-3.79B | 0.82%-2.48B | -3.11%-1.15B | 10.58%-6.35B | -5.28%-4.09B | -4.69%-2.5B | -5.53%-1.12B | -36.26%-7.11B | -60.86%-3.89B |
Gross profit | 10.83%3.35B | 1.14%2.58B | 3.22%1.64B | 14.63%753.67M | -20.22%3.02B | -7.20%2.56B | -12.96%1.59B | -27.36%657.46M | 34.57%3.78B | 148.23%2.75B |
Selling expenses | 44.38%-19.79M | 43.64%-14.58M | 31.87%-11.83M | 46.04%-7.21M | 40.41%-35.58M | 42.12%-25.86M | 42.00%-17.36M | -49.68%-13.37M | -12.53%-59.7M | -145.18%-44.69M |
Administrative expenses | -8.89%-483.18M | 7.38%-286.9M | 5.49%-182.67M | -7.10%-94.25M | 22.41%-443.72M | -19.16%-309.77M | -13.51%-193.28M | -6.21%-88M | -57.50%-571.85M | -51.73%-259.97M |
Research and development expenses | 27.97%-33.48M | 25.93%-19.8M | 23.84%-13.91M | 34.06%-6.08M | 23.27%-46.48M | -4.70%-26.73M | 8.11%-18.26M | 30.77%-9.22M | -3.20%-60.57M | -47.49%-25.53M |
Profit from asset sales | 87.11%13.65M | 163.40%12.75M | 163.89%12.75M | -103.85%-12.44K | -58.04%7.3M | -67.97%4.84M | -68.27%4.83M | -100.04%-6.1K | 23,234.93%17.39M | 5,719.15%15.12M |
Revaluation surplus | 61.39%153.61M | 214.61%162.43M | 33.99%148.23M | 176.74%548.87K | -72.67%95.18M | -26.69%51.63M | 300.71%110.63M | -563.63%-715.19K | 14,964.16%348.27M | 333.44%70.43M |
-Changes in the fair value of other assets | 61.39%153.61M | 214.61%162.43M | 33.99%148.23M | 176.74%548.87K | -72.67%95.18M | -26.69%51.63M | 300.71%110.63M | -563.63%-715.19K | 14,964.16%348.27M | 333.44%70.43M |
Impairment and provision | 6.03%-232.43M | -100.07%-53.48M | -137.22%-56.79M | -262.17%-883.1K | -46.11%-247.34M | -881.11%-26.73M | -598.83%-23.94M | -67.49%544.54K | -250.34%-169.29M | 188.28%3.42M |
-Other impairment is provision | 6.03%-232.43M | -100.07%-53.48M | -137.22%-56.79M | -262.17%-883.1K | -46.11%-247.34M | -881.11%-26.73M | -598.83%-23.94M | -67.49%544.54K | -250.34%-169.29M | 188.28%3.42M |
Special items of operating profit | -0.97%1.55B | -53.97%668.96M | 8.03%377.37M | -1.62%214.31M | 55.00%1.57B | 86.50%1.45B | -40.04%349.33M | -11.72%217.83M | 2.64%1.01B | 101.65%779.19M |
Operating profit | 9.81%4.25B | -17.11%3.02B | 6.33%1.9B | 12.66%852.2M | -8.22%3.87B | 12.71%3.65B | -15.45%1.79B | -26.47%756.41M | 31.72%4.22B | 162.62%3.24B |
Financing cost | 10.56%-1.24B | 14.91%-955.34M | 7.47%-664.49M | -13.37%-259.93M | -52.53%-1.39B | -55.30%-1.12B | -64.02%-718.16M | 2.73%-229.28M | -84.95%-909.12M | -68.80%-722.95M |
Special items of earning before tax | -3,726.65%-97.78M | -1,182.97%-80.72M | -882.06%-32.89M | -160.14%-1.51M | -105.58%-2.56M | -43.77%7.45M | -61.94%4.21M | 0.21%2.5M | 1,532.38%45.75M | 316.21%13.25M |
Earning before tax | 17.35%2.92B | -21.51%1.99B | 12.09%1.2B | 11.54%590.76M | -25.99%2.48B | 0.23%2.53B | -36.40%1.07B | -33.42%529.63M | 23.90%3.36B | 216.68%2.53B |
Tax | -0.09%-529.8M | 7.58%-428.22M | -41.15%-270.25M | -34.67%-122.26M | 3.96%-529.32M | -9.44%-463.36M | 47.43%-191.46M | 49.81%-90.78M | -16.30%-551.15M | -183.66%-423.4M |
After-tax profit from continuing operations | 22.02%2.39B | -24.63%1.56B | 5.77%930.82M | 6.76%468.51M | -30.32%1.96B | -1.63%2.07B | -33.36%880.03M | -28.60%438.85M | 25.51%2.81B | 224.28%2.1B |
Earning after tax | 22.02%2.39B | -24.63%1.56B | 5.77%930.82M | 6.76%468.51M | -30.32%1.96B | -1.63%2.07B | -33.36%880.03M | -28.60%438.85M | 25.51%2.81B | 224.28%2.1B |
Minority profit | 195.66%58.63M | -60.47%19.68M | -95.06%1.55M | 0.79%25.95M | -131.79%-61.29M | -71.87%49.79M | -72.03%31.32M | -63.25%25.75M | 6.52%192.84M | 1,955.26%177M |
Profit attributable to shareholders | 15.41%2.33B | -23.75%1.54B | 9.49%929.28M | 7.13%442.55M | -22.83%2.02B | 4.83%2.02B | -29.78%848.71M | -24.14%413.1M | 27.19%2.61B | 192.67%1.93B |
Basic earnings per share | 17.04%0.982 | -25.44%0.642 | 10.66%0.384 | 8.33%0.182 | -24.62%0.839 | 5.13%0.861 | -32.23%0.347 | -26.64%0.168 | 18.40%1.113 | 171.19%0.819 |
Diluted earnings per share | 17.04%0.982 | -25.44%0.642 | 10.66%0.384 | 8.33%0.182 | -24.62%0.839 | 5.13%0.861 | -32.23%0.347 | -26.64%0.168 | 18.40%1.113 | 171.19%0.819 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data